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Summary Because side-effects of chemotherapy may be more diverse and patients' reactions more individualistic than tends to be
acknowledged by clinicians, a survey was carried out among 50 breast cancer outpatients to document self-reported physical symptoms
experienced during NCF (mitoxantrone +cyclophosphamide +5-fluorouracil) adjuvantchemotherapy and to compare them with the clinicians'
estimation in medical records. The questionnaire evaluated the prevalence, duration/severity and distress level of 17 symptoms. Symptom
prevalence, assessed in 231 cycles, was high even for symptoms that do not usually focus clinicians' attention. Ofthese, hotflushes, stomach
pain and muscular and articular pains lasted 1 week or more for nearly half of the cycles. Hot flushes, vomiting and stomach pain were the
most distressing symptoms. The mean number of symptoms per cycle is significantly correlated with the global quality-of-life score.
Concordance between patients' self-assessment and clinical reports, measured in 180 cycles, is moderately correct for vomiting and sore
mouth and inadequate forthe remaining symptoms even for hair loss (notified in 27% of cycles by clinicians vs 80% by patients) and nausea
(38% vs 73%). A better understanding by physicians of cancer patients' problems is necessary to improve quality of care.
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It is well established that somatic symptoms condition cancer
patients' acceptability of treatments and that side-effects of
chemotherapy may create barriers to patients' acceptance and
compliance with effective adjuvant therapies before and during
treatment (Love et al, 1989; Cooper and Georgiou, 1992;
Fallowfield, 1992). Oncologists' attention has, however, been
mainly focused on toxicity of chemotherapy and on some of its
most noticeable associated side-effects (hair loss, nausea and
vomiting) (Coates et al, 1983; Griffin et al, 1996; Morrow, 1996).
In recent years, there have been more systematic attempts to
measure the impact of side-effects on patients' well-being and
quality of life during chemotherapy treatments by taking into
account patients' subjective point of view (Coates et al, 1983,
1987; Knobf, 1986; Byrne, 1992; Payne, 1992; Griffin et al, 1996;
Swain et al, 1996). However, it is obvious that such approaches
have not yet been fully integrated in day-to-day clinical practice in
oncology (Waitzkin, 1984; Sutherland et al, 1989).
Because side-effects ofchemotherapy may be more diverse and
reactions of patients more variable and individualistic than tends
to be acknowledged by clinicians, we have carried out a study
among standard risk breast cancer patients to compare their own
self-assessment ofphysical symptoms and associated distress they
experience during adjuvant chemotherapy with the estimation by
clinicians as it appears in medical records.
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PATIENTS AND METHODS
Patient selection
The study was carried out in the outpatient clinic of the Paoli-
Calmettes Institute (Regional Center for Cancer Care and
Research of Marseilles in south-eastern France) between July
1994 and July 1995. All breast cancer patients with no metastases
and less than nine axillary nodes involved, receiving an adjuvant
NCF polychemotherapy, comprising Mitoxantrone (12 mg m-2),
cyclophosphamide (500 mg m-2), and 5-fluorouracil (500 mg m-2),
i.v. administered in six cycles of 21 days, and concomitant radio-
therapy were included in the study. Tamoxifen (20 mg daily) was
given for 3 years to women with confirmed menopausal status at
diagnosis and with positive hormonal receptors. It was started only
at the end ofthe chemotherapy and radiotherapy sequence.
Patients' self-assessment
Before starting a new cycle of chemotherapy, each patient was
asked to complete a written self-administered questionnaire about
the side-effects she had experienced during the previous cycle and
herglobal quality oflife during this period. The last questionnaire,
assessing the side-effects effects related to the sixth cycle of
chemotherapy, was completed by the patient at home and returned
to the medical team during a follow-up consultation or sent by
mail with a stamped-addressed envelope, Each questionnaire took
approximately 10 min to complete.
The questionnaire included a list of 17 symptoms commonly
associated with chemotherapy for breast cancer: nausea, vomiting,
lack of appetite, diarrhoea, weight loss and gain, sore mouth,
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stomach pain, headache, hair loss, skin rash, articular and
muscular pain, cystitis, menstruation problem, hot flush and fever.
For each symptom, patients were asked three times: (a) if they
had experienced this symptom at least once during the previous
3 weeks (yes or no); (b) what was the duration of such a symptom
(using a four-point scale: less than 2 days, 3-6 days, 1 or 2 weeks,
all the time); and (c) to what extent the symptom had been
disturbing forthepatient (using afour-pointLikert scale: not at all,
a little bit, quite a bit, very much). Because duration was not rele-
vant for three symptoms (hair and weight loss/gain), severity was
evaluated instead.
Global ratings of physical status and quality of life during the
previous 3 weeks were also obtained using similar items to those
included in the EORTC QLQ-C30 questionnaire (items 29 and 30)
(Aaronson et al, 1993). A score of 1 was assigned to a 'very poor'
physical status or global quality of life and 7 to an 'excellent'
physical status orglobal quality oflife. At the end ofthe question-
naire, a comment section was added and patients were encouraged
to report any other physical problems experienced during the
chemotherapy course, as well as their duration/severity and the
distress that was associated with it.
Physicians' assessment
Physicians' evaluations of the same 17 symptoms, estimated by
them foreach cycle ofchemotherapy, were directly collected from
medical records. A standardized sheet about toxicity oftreatment,
containing the same list of symptoms as in the patients' question-
naire, had been introduced 6 months previously in the routine
medical record of the clinic. At the time of the consultation,
carried out before the start of each cycle of chemotherapy, clini-
cians routinely asked the women about the side-effects they had
experienced during the previous cycle. The standard sheet is used
to guide them in this task and to make reporting of symptoms
easier. Symptoms are assessed in terms ofpresence or absence.
Data analysis
A questionnaire was excluded from analysis ifthe answers to more
than 10% of items were missing, duration/severity and distress
associated with each symptom being considered as separate items
for this calculation. The missing values were treated as follows: if,
for example, in the questionnaire completed by a patient at the
third cycle of chemotherapy, duration of nausea was missing, we
assigned the median value ofpatients' answers to this item for the
same third cycle oftreatment. A global quality-of-life score (QOL
score) was calculated as the mean of the scores on the two scales
corresponding to global health and global quality of life. This
score was linearly transformed to a 0-100 score, with a higher
score representing a higher level of global quality of life
(Aaronson et al, 1993).
Spearman coefficients were calculated to investigate correla-
tions between answers about duration/severity of each symptom
and answers about the distress associated with each of them, as
well as correlations between mean number of declared symptoms
during each cycle of chemotherapy and global QOL score.
Cochran and Friedman non-parametric tests were used to test
for significant changes over time among the subgroup of patients
who completed a questionnaire at each of the six cycles of
chemotherapy (n = 30). To compare patients' declarations about
prevalence of symptoms with those reported by the physicians,
Table 1 Clinical characteristics of the consenting patients (n= 50)
Characteristic n %
Histological type
Ductal adenocarcinoma 34 68
Lobular adenocarcinoma 3 6
Other histological type 13 26
AJCC stage
1 18 36
11 25 50
III 3 6
Not applicable* 4 8
SBR grading
7 14
11 23 46
III 16 32
Not done 4 8
Axillary nodes
N- 14 28
1-3 28 56
>3 8 16
Hormonal receptors
Positive 23 46
Negative 20 40
Unknown 7 14
Menopausal status
Menopausal 24 48
Non-menopausal 26 52
*These four patients presented a local relapse but they had not received
earlier chemotherapy.
Cohen's Kappa coefficient was used as the measure of agreement
between the two types ofevaluation (Fliess, 1981).
RESULTS
Fifty-two patients, aged between 32 and 70 years (median = 51),
were asked toparticipate in the study, starting atdifferentcycles of
their treatment. Only two patients refused to participate (participa-
tionrate 96%). A subgroup of33 patients were askedtoparticipate
for the whole course oftheir treatment, that is from the first to the
sixth cycle of chemotherapy. Three patients in this group did not
complete one ofthe six questionnaires.
After exclusion of one questionnaire with more than 10% of
items not answered, a total of 231 questionnaires were available
for statistical analysis 40, 43, 40, 38, 38 and 32 from the first to the
sixth cycle of chemotherapy respectively. The average rate of
missing values was 2.3% for the items of the duration/severity
dimension and 6% for the items on the distress dimension. It must
be noted that, for the calculations ofmissing values as well as for
the further analyses, the item 'menstruation problems' was
discarded because of the unsuitable formulation of the corre-
sponding question.
All the patients were able to complete the questionnaire without
assistance. Most of them had no problem in understanding ques-
tions, except the one relating to the above-mentioned symptom.
The clinical characteristics of the consenting patients (n = 50) are
displayed in Table 1.
Table 2 summarizes the patients' declared frequency of symp-
toms, theirduration/severity and thedegree ofdistress thatpatients
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Table 2 Prevalence and characteristics of symptoms, when present, evaluated by the study patients in 231 chemotherapy cycles
Frequency Duration/severitya Distressa
1-2 daysb 3-6 daysc .7 daysd Not at all A little bit Quite a bit/very much
Symptom n % % % % % % %
Hair loss 178 77 50 32 18 14 36 50
Nausea 176 76 25 54 21 2 41 57
Hot flush 134 58 10 18 72 1 22 77
Lack of appetite 109 47 23 39 38 23 25 52
Headache 102 44 46 40 14 4 55 41
Stomach pain 88 38 15 39 46 1 28 71
Sore mouth 69 30 23 38 39 4 46 50
Muscular pain 69 30 26 25 49 3 46 51
Vomiting 67 29 46 51 3 2 25 73
Articular pain 65 28 29 25 46 7 48 45
Skin rash 55 24 38 27 35 7 47 46
Weight loss 51 22 44 32 24 53 29 18
Weight gain 44 19 45 33 22 26 39 35
Diarrhoea 39 17 58 33 9 24 43 33
Fever 30 13 55 32 13 14 39 47
Cystitis 23 10 48 17 35 4 54 42
aWhen the symptom is present. The number of respondents is shown in the first column; it may vary slightly because of missing data.
bHair loss, a little bit; weight loss/gain, 1 kg; cHair loss, quite a bit, weight loss/gain, 2 kg; dHair loss, very much/completely; weight loss/gain, .3 kg.
Table 3 Correlation between the mean number of symptoms and QOL score at each cycle of chemotherapy
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
(n= 40) (n=43) (n= 40) (n=38) (n=38) (n=32)
Mean number of symptoms 5.5 ± 3.1 5.7 ± 2.9 6.0 ± 3.1 6.2 ± 2.7 6.8 ± 2.7 6.3 +2.4
Mean QOL score 59.7 ± 18.8 57.5 ± 19.9 51.9 ±21.7 51.9±16.6 48.5 ± 15.7 46.9 ± 15.9
Correlation coefficient (r) -0.37* -0.44 -0.60** -0.49 -0.47 -0.45
*P<0.05; **P<0.001; P<0.01 for all other statistics.
associated with them during the 231 cycles of chemotherapy for
which we have valid information. Not surprisingly, frequency is
high even for symptoms such as hot flushes, lack of appetite,
headaches, stomach pain and muscular and articular pains, which
do not usually attract a lot of clinical attention. Some of these
frequent symptoms (hot flushes, stomach, muscular and articular
pains) tended to last 1 week or more for nearly half of the cycles.
When present, sore mouth, lack ofappetite, skin rashes and cystits
also last at least 1 week for more than a third of cycles. Although
the most frequent, hair loss is considered as severe for only 18% of
cycles. Hot flushes, vomiting and stomach pain are the most
disturbing symptoms for the patients. In addition, in the open
section, tiredness, change in taste and conjunctivitis were symp-
toms spontaneously mentioned by patients in more than 10% of
the questionnaires.
For each symptom, mean scores were calculated, on all the
cycles of chemotherapy, for the answers relating to
duration/severity and the answers about degree of associated
distress. Pairwise interdimension correlations were calculated
between these two scores and revealed statistically significant rela-
tionships (P < 0.05) between duration/severity of a symptom and
its impact on patient's distress in the cases of lack of appetite
(r = 0.92), diarrhoea (r = 0.69), hot flush (r = 0.55), headache
(r = 0.54), weight gain (r = 0.54), hair loss (r = 0.51) and articular
pain (r = 0.51). It must be noted that no statistically significant
relation was found between duration of episodes of vomiting or
nausea and patients' associated distress, suggesting that even
limited episodes may be sufficient to disturb patients.
Table 3 shows that the mean number of symptoms declared per
cycle by patients is significantly correlated with their global
quality-of-life score during this cycle: the more patients experi-
ence physical symptoms during a cycle ofchemotherapy, the lower
their QOL score during this period. Moreover, global quality of
life, already moderate during the first cycle ofchemotherapy, regu-
larly decreases over time, whereas the number of physical symp-
toms increases.
In the subgroup of30 patients who completed a questionnaire for
each of their six chemotherapy cycles (Table 4), the declared
frequency of symptoms tended to remain constant across cycles,
with two exceptions: hot flushes, which were only mentioned by
47% ofpatients at first cycle but 70% at the last one, and hair loss,
which increased from 53% to 93% ofpatients between cycle 1 and
cycle 6. Nevertheless, only frequency of hair loss demonstrates a
statistically significant change over time (P< 0.001). The mean
score for severity of hair loss also significantly increases (from
1.1±0.3 at cycle I to 1.8± 0.7 at cycle 6, P < 0.05) as well as the
mean score for associated distress (1.9 ± 0.8 vs 2.7 ± 0.9, P < 0.05).
Figure 1 compares the frequency of declaration of each
symptom, during the 180 cycles of chemotherapy of these 30
patients, to those noted by clinicians in their medical records.
Concordance between patient's self-assessment and clinical
reports is moderately correct (Kappa coefficient between 0.45 and
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Table 4 Evolution of symptom prevalence during the chemotherapy in 30 patients having completed the questionnaire at each cycle of chemotherapy
Symptom Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle5 Cycle 6
n % n % n % n % n % n %
Nausea 22 73 22 73 23 77 23 77 25 83 23 77
Vomiting 8 27 6 20 8 27 8 27 10 33 14 47
Lack of appetite 13 43 13 43 16 53 13 43 18 60 13 43
Diarrhoea 4 13 6 20 5 17 7 23 7 23 5 17
Weight loss 22 73 8 27 8 27 5 17 5 17 5 17
Weight gain 7 23 7 23 5 17 7 23 5 17 5 17
Sore mouth 8 27 8 27 10 33 10 33 12 40 8 27
Stomach pain 11 37 14 47 10 33 13 43 10 33 12 40
Headache 14 47 13 43 14 47 13 43 13 43 12 40
Hair loss 16 53 20 67 23 77 27 90 26 87 28 93
Skin rash 7 23 8 27 7 23 7 23 8 27 8 27
Muscular pain 5 17 8 27 12 40 10 33 12 40 9 30
Articular pain 8 27 8 27 9 30 8 27 10 33 8 27
Hot flush 14 47 15 50 17 57 20 67 20 67 21 70
Fever 4 13 4 13 4 13 5 17 5 17 4 13
Cystitis 3 10 4 13 2 7 2 7 5 17 4 13
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Figure 1 Comparison of chemotherapy side-effects evaluated by patients with those reported by physicians in medical records (n = 30,180 cycles of
chemotherapy), *, Patient; physician; (,Cohen's Kappa coefficient; *P < 0.05; **P<10-2; ***P < 10-3; NS, not significant
0.75; Landis and Koch, 1977) for only two symptoms (vomiting DISCUSSION
and sore mouth) and totally inadequate for the remaining 14 symp-
toms. Discordance between patients and clinicians' reports even The aim of this study was to document self-reported physical
concerns such usual side-effects of chemotherapy as hair loss symptoms experienced by breast cancer patients during adjuvant
(notified in only 27% of cycles by clinicians vs 80% by patients) chemotherapy and to compare them with clinicians' estimations in
and nausea (38% vs 73%). Some ofthe most disturbing symptoms medical records. The questionnaire presented to patients was well
from the patients' perspective (hot flushes, stomach pain, lack of accepted and, in all cases, it could be completed without assistance
appetite and muscular pain) are systematically underestimated in as a guarantee of a true self-assessment. One criticism that could
medical records. be made ofthis study is that the sample size is relatively small, this
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may limit the generalization of our findings. However, with data
being collected at each cycle of chemotherapy, the side-effect
prevalence was finally calculated in 231 cycles of chemotherapy
and the comparison between patients' and physicians' evaluations
in 180 cycles. Concerning the patients vs physician comparative
study, it has been verified that there was no significant statistical
difference between the group ofpatients included (n = 30) and the
group ofpatients not included (n = 20) in this study, for all clinical
characteristics (particularly forage, menopausal status and number
of axillary nodes involved). Only the evolution of patterns of
patient-reported side-effects during the subsequent six
chemotherapy cycles has to be considered with caution because
the frequency of symptoms, at each cycle, is calculated in only 30
cases. Statistical comparisons throughout the six cycles of
chemotherapy perhaps may not have sufficient power.
The identification of physical symptoms experienced by
patients and appreciation oftheirimpact on theirwell-being during
treatment should be information of primary interest for oncolo-
gists. The deterioration of patients' physical status due to the
adverse effects ofchemotherapy is likely to have repercussions on
the acceptability of treatment, anxiety, mood, the quality of their
family life and social relations as well as their ability to cope with
their illness. Our study confirms the evidence ofprevious research
(Love et al, 1989; Portenoy et al, 1994a) that the number of
disturbing physical symptoms experienced by cancer patients is
strongly associated with their overall quality of life during
chemotherapy treatment. Our study, carried out in a group of
female patients with standard risk breast cancer, also found similar
frequencies ofsymptoms, such as nausea and vomiting, associated
with NCF chemotherapy as in other groups ofpatients (metastatic
breast cancers) receiving the same regimen (Bennett et al, 1988).
Detailed comparison of our findings with those of this previous
study are difficult, and a more systematic investigation in our own
sample may explain higher frequencies of declarations for symp-
toms such as hair loss (77% vs 49%) or sore mouth (30% vs 10%).
Moreover, our study points out both frequency and distress of
some symptoms associated with NCF chemotherapy that have
been rather neglected by previous studies and in general by clini-
cians, such as hot flushes, stomach pain, lack of appetite, myalgia
and arthralgia, which are experienced in at least a third of
chemotherapy cycles. Ofcourse, some ofthese symptoms may not
be directly caused by toxicity ofchemotherapeutic drugs and may
be related to some of the patient characteristics (for example,
menopausal status), to other aspects of treatment or to emotional
dimensions universally associated with breast cancer disease
(Koller et al, 1996). However, the fact remains that our study
strongly suggests that clinicians often underestimate many somatic
symptoms whose improvement may require specific intervention
and therefore have a positive impact on patients' overall well-
being during treatment. Nevertheless, the case of hot flushes,
which were frequent in our study during chemotherapy although
patients were not yet treated with tamoxifen, poses a difficult
problem for medical teams. Amelioration of hot flushes is limited
as it is not possible to have recourse to oestrogen therapy. As the
non-hormonal treatments used for menopausal hot flushes, such as
methyldopa and clonidine, are poorly effective (Nesheim and
Saetre, 1981; Goldberg et al, 1994), preference is given at the
Paoli-Calmettes Institute to other drugs acting on the central
nervous system, such as barbiturates orneuroleptics. Nevertheless,
as the elimination ofhot flushes is uncertain, it is important before
the start of chemotherapy to provide women with the most
comprehensive information on the potential occurrence of this
symptom and its cumulative effect across cycles. Given the low
emetic effect of the NCF chemotherapy, the high frequency of
nausea experienced by patients in this study is surprising. This
finding has led us to undertake a study for the management of
nausea in patients receiving this type of chemotherapy by using
antiemetic agents that act by selective 5-HT3 blocking.
It can also be argued thatunderestimation ofpatients' symptoms
is less important in real clinical practice than can be observed on
the basis of medical records. Some symptoms may have been
recognized byphysicians and even discussed in clinical interaction
with patients, but not reported in medical files. It must be noted,
however, that this bias was minimized in our study as a specific
sheet about symptoms potentially associated with the side-effects
of chemotherapy has been included in the routine medical records
of the clinic in which data were collected, and that clinicians were
aware of the study and its focus on these side-effects. It can even
be stressed that not reporting a patient's recognized symptom is
very likely to indicate that clinicians do not consider this informa-
tion as meaningful for care.
Clinicians' underestimation of somatic symptoms during NCF
chemotherapy that seem important from the patients' perspective
confirms other findings from various social science research
applied to health that physicians' ratings do not always accurately
reflect the functional health and symptom experience of their
patients (Tierney et al, 1991; Da Silva et al, 1996). Under-
estimation of pain intensity, and consequently inadequacy of
medication for pain relief, seems to be one of the main areas in
which medical staffprovide ratings that diverge from those oftheir
patients (Sprangers et al, 1992). In our study, discrepancies
between patients' self-assessment and medical records tend to
encompass a whole range of somatic symptoms. It suggests that
oncologists, at least in our French context, may not have a fully
accurate picture of chemotherapy tolerance. Although it has been
clearly established that reciprocal information on side-effects and
more widely on quality oflife during treatment is an important part
of doctor-patient communication (Cooper and Georgiou, 1992;
Ong et al, 1995), our study points out practical difficulties that
surely affect the quality of this communication in oncology.
In conjunction with a global social trend for the promotion of
patients' autonomy, many observers ofthe health care system, and
some clinicians themselves, are currently advocating a shared
decision-making model between patients and physicians (Eddy,
1990; Deber, 1994). The extent to which patients really want to be
directly involved in therapeutic choices, especially when survival
is at stake, as in the case ofbreast cancer, remains highly debatable
(Sutherland et al, 1989; Degner and Sloan, 1992). However, many
studies vouch for the fact that cancer patients have a strong desire
and need for information about their diagnosis, prognosis and
treatment (McIntosh, 1974; Molleman et al, 1984; Blanchard et al,
1994), with a special emphasis on information about the potential
side-effects of treatment (Cassileth et al, 1980; Tierney et al,
1991). Some studies have even reported that cancer patients
declaring high levels of satisfaction with the information that was
provided for them by medical staff were less anxious and coped
better than other patients (Steptoe et al, 1991).
Although specific to the case of NCF chemotherapy in breast
cancer patients, our study suggests that an improvement in
clinician-patient dialogue about symptoms can make a significant
contribution to the quality of care in oncology. First, the role of
patients as the best source of information about their own symptoms
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should be better recognized. The fact that, among our patients,
frequency of symptoms such as headaches, hot flushes, stomach
pain, myalgia and arthralgiaremained constantthroughout the whole
course ofsix cycles ofchemotherapy suggests that the medical team
may not have focused enough attention on and consequently inter-
vene in these patients' problems. This is also very likely to be the
case for psychological symptoms, which were not included in our
study, and need furtherinvestigation. Apractical consequence ofour
study, which is already implemented atthe Institute Paoli-Calmettes,
is to recommend a more open-minded approach to the routine
medical monitoring ofpatients' problems during chemotherapy. The
systematic use ofa patient's self-report during the medical consulta-
tionafterthefirstcycleofchemotherapythatprovides clinicians with
useful information on side-effects and associated distress experi-
encedby patients helps open adialogue onthese matters.
Secondly, the patients' point of view is the key to helping clini-
cians better understand which aspects of care are relevant for their
quality of life and well-being, and the relative importance patients
really attach todifferent aspects ofcare. Ourstudy shows, like others
(Portenoy etal, 1994b), thatinformation on symptomfrequency may
not be sufficient for adequate care during chemotherapy and should
be completed by clinicians' knowledge ofduration and intensity of
symptoms as well as intensity of distress expressed by patients in
relation to these symptoms. It is also worth noting that some of the
mostdistressing symptoms forpatients were notthoseanticipatedby
us. Forexample, hairloss did not appearamong the most distressing
symptoms, but this may be due to the less severe alopecia associated
with mitoxantrone compared with other chemotherapeutic drugs
(Bennetetal, 1988) andwiththecorrelationbetweenintensity ofhair
loss and increased distress expressed by patients on that matter.
Finally, our study suggests that abetterknowledge ofdistress associ-
ated with treatment side-effects would facilitate clinical decision
making and side-effect management in thepractice setting.
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